Most important in brief
- Pembrolizumab: as a first treatment alone or with chemotherapy, and around surgery, before it together with chemotherapy and after it alone.
- Atezolizumab: as a first treatment alone or in combination, after complete surgery with PD-L1 of 50% or more, and for extensive-stage small cell lung cancer with carboplatin and etoposide.
What applies now
Federation of Bosnia and Herzegovina
Solidarity Fund list (version 47/19, last amended by 76/26) · List (PDF), September 2026 update · checked on 19 November 2026
Hospital cancer medicines are paid by the Solidarity Fund, not the regular medicines list. The list includes standard chemotherapy, erlotinib, crizotinib, alectinib, nivolumab, pembrolizumab, atezolizumab and dabrafenib with trametinib (explicitly as first treatment for advanced NSCLC). Since September 2026 the list names lung cancer explicitly for pembrolizumab and atezolizumab: both as a first treatment alone or with chemotherapy and after complete surgery, pembrolizumab also before surgery, and atezolizumab also for extensive-stage small cell lung cancer.
Not on the list
Osimertinib, lorlatinib, brigatinib, durvalumab, and no medicine against KRAS G12C, RET, MET, NTRK or HER2.
What this means for you
If you are treated in the Federation, pembrolizumab and atezolizumab are now explicitly on the list for lung cancer: as a first treatment for advanced disease, usually without an EGFR or ALK change, and around surgery.
For extensive-stage small cell lung cancer this also applies to atezolizumab with chemotherapy.
This decision does not change anything in Republika Srpska. There, ask your care team what is paid.